Abstract

Traumatic or degenerative joint pain is abundant in the population. Symptom relief by intra- and periarticular glucocorticoid administration is frequently used, however may have potentially devastating effects, changing the normal healing process of the joint. Mesenchymal stem cells (MSCs) are important for wound-healing processes due to their multipotency in regenerating osteoblasts, chondrocytes and adipocytes but also have immunomodulatory properties. The aim of this study was to investigate the impact of triamcinolone acetonide (TA) a common glucocorticoid administrated intra- and periarticularly, on human bone marrow derived MSC viability, functionality, multi-lineage differentiation and transcriptomic output. We found that TA treatment induced apoptosis and promoted adipogenesis while impairing chondrogenesis of MSCs. RNA sequencing indicated that TA modulated the inflammatory response of MSCs, which may have an impact on the immunologic environment where the inflammatory phase is a physiological part of the natural healing process. These data indicate that triamcinolone acetonide should be used with consideration bearing the patient’s outcome in mind, with the intention to optimize joint recovery and homeostasis.

Details

Title
The functional and molecular impact of triamcinolone acetonide on primary human bone marrow mesenchymal stem cells
Author
Kumlin, Maritha 1 ; Ungerstedt, Johanna 2 ; Cai, Huan 3 ; Leonard, Elory 3 ; Felländer-Tsai, Li 1 ; Qian, Hong 3 

 Karolinska Institutet, K54, Division of Orthopaedics and Biotechnology, Department of Clinical Science, Intervention and Technology (CLINTEC), Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Karolinska Institute, Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine (HERM), Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, ME Hematology, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705) 
 Karolinska Institute, Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine (HERM), Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
Pages
21787
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2899560976
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.